Overexpression of other receptor tyrosine kinases, including HER2, HER3, MPM7, and coexpression of all four HER family member (HER1, HER2, HER3, HER4) receptors, also may contribute to tumor resistance to EGFR-targeting agents [26,42,43,44]. The gene discussed is EGFR; the disease is neoplasm.